Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 9:14:1455428.
doi: 10.3389/fonc.2024.1455428. eCollection 2024.

Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?

Andrea Lancia  1 , Gianluca Ingrosso  2 , Beatrice Detti  3 , Eleonora Festa  2 , Elisabetta Bonzano  1 , Flavia Linguanti  4 , Federico Camilli  2 , Niccolò Bertini  5 , Salvatore La Mattina  1 , Carolina Orsatti  5 , Giulio Francolini  5 , Elisabetta Maria Abenavoli  6 , Lorenzo Livi  5 , Cynthia Aristei  2 , Dorine de Jong  7 , Karine A Al Feghali  7 , Shankar Siva  8   9 , Carlotta Becherini  5
Affiliations
Review

Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?

Andrea Lancia et al. Front Oncol. .

Abstract

The therapeutic landscape of metastatic prostate cancer has undergone a profound revolution in recent years. In addition to the introduction of novel molecules in the clinics, the field has witnessed a tremendous development of functional imaging modalities adding new biological insights which can ultimately inform tailored treatment strategies, including local therapies. The evolution and rise of Stereotactic Body Radiotherapy (SBRT) have been particularly notable in patients with oligometastatic disease, where it has been demonstrated to be a safe and effective treatment strategy yielding favorable results in terms of disease control and improved oncological outcomes. The possibility of debulking all sites of disease, matched with the ambition of potentially extending this treatment paradigm to polymetastatic patients in the not-too-distant future, makes Biology-guided Radiotherapy (BgRT) an attractive paradigm which can be used in conjunction with systemic therapy in the management of patients with metastatic prostate cancer.

Keywords: PET/CT; biology-guided radiotherapy; metastases; prostate cancer; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Authors DD and KA were employed by the company RefleXion Medical, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. (2023) 73:17–48. doi: 10.3322/caac.21763 - DOI - PubMed
    1. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. . The evolutionary history of lethal metastatic prostate cancer. Nature. (2015) 520:353–7. doi: 10.1038/nature14347 - DOI - PMC - PubMed
    1. Langley RR, Fidler IJ. The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. (2011) 128:2527–35. doi: 10.1002/ijc.26031 - DOI - PMC - PubMed
    1. Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. (2017) 8:3724–45. doi: 10.18632/oncotarget.v8i2 - DOI - PMC - PubMed
    1. Al-Toubat M, Serrano S, Elshafei A, Koul K, Feibus AH, Balaji KC. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis. Urol Oncol. (2023) 41 (11):455.e7–.e15. doi: 10.1016/j.urolonc.2023.09.014 - DOI - PubMed

LinkOut - more resources